IKIkechukwu Kanu

Ikechukwu Kanu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ikechukwu Kanu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Genomics of Zoonotic Pathogens: Genetic Determinants of Host Switching and Cross-Species Transmission

    by Olabisi Lawal, Ezekiel Tosin Babatunde, Ismaila Muhammed, Quadri N. Okiki, Eze Samson Chibueze, Victor Omeiza David, Caleb Otabil, Okabeonye Sunday Agbo, Ikechukwu Kanu, Oyebamiji Abdulhalim Ololade

    Emerging infectious diseases of animals that spread to humans (zoonoses) continue to represent a major threat to public health throughout the world. Knowledge of genetic elements that enable pathogens to navigate host shifts and species jumps is crucial for predicting and preventing zoonotic cross-species transmission. Comparative genomics, comparing whole-genome sequences across a range of hosts and pathogens, provides a powerful means to dissect the molecular determinants of zoonotic emergence. Here, we summarize and discuss recent advances in the understanding of genetic modifications that enable host switching and cross-species transmission by selected zoonotic pathogens. We review how comparative genomic analyses revealed the critical importance of factors such as receptor-binding domain evolution, immune evasion genes, and virulence determinants in improving pathogen fitness in new hosts.The review also highlights the integration of genomic data into One Health surveillance frameworks, enabling real-time monitoring, early detection, and improved outbreak response. Despite these advances, challenges including sampling bias, incomplete genomic databases, misannotation, and the complexity of predicting phenotype from genotype limit the field’s potential. Furthermore, ethical and biosafety concerns in studying high-risk zoonotic pathogens necessitate careful governance. We outline future directions, emphasizing the need for expanded wildlife sampling, longitudinal studies of host-pathogen co-evolution, and the application of artificial intelligence in zoonotic risk assessment. Building comprehensive, globally accessible genomic databases is essential for coordinated pathogen tracking and risk mitigation. Ultimately, comparative genomics is indispensable for understanding and managing zoonotic threats, and its continued advancement, integrated within interdisciplinary, data-driven One Health strategies, will be critical to preventing future pandemics.

  • Surface functional group dependent enthalpic and entropic contributions to molecular adsorption on colloidal microplastics

    by Ikechukwu Kanu, Amrit Ojha, Kalie Adams, Jacob Brooks, Mahamud Subir

    Influence of soft polymeric hair-like structure of colloidal microplastics on molecular adsorption thermodynamics is revealed by in situ SHG experiments.


  • Role of HLA Class I Molecule in Cancer: Implications for Cancer Immunotherapy

    by Josiah Stephen, Ikechukwu Kanu, Nwamaka Nneka Onyedum, Enibokun Theresa Orobator, Catherine Rono, Chinaza Faith Ngwoke, Victor Omeiza David, Wonderful Oluwatoyin Anosike, Lawrence John Ajutor

    HLA class I molecules are essential for presenting tumour antigens to cytotoxic T-cells, but their dysregulation in cancer enables immune evasion and limiting the efficacy of immunotherapies for cancer. The objective of this review is to explore the function of HLA class I changes in cancer development and their consequences for immunotherapy evolution. Examining peer-reviewed studies from 2010–2025 in PubMed and Scopus, a thorough literature review was done with a focus toward HLA class I expression, genetic defects, and immunotherapy outcomes in cancers including melanoma and lung cancer. HLA Class I Downregulation is a hallmark of tumour cells. Findings show that epigenetic silencing, β2-microglobulin mutations, or altered antigen-processing machinery are identified as the major mechanisms of HLA downregulation observed in 50–70% of tumours. These alterations are primary to therapeutic implications like poor responses to drugs like checkpoint inhibitors and they cause decreased T-cell infiltration. Research shows that in preclinical models, restoring HLA class I expression through cytokines, epigenetic modulators, or gene therapy are effective strategies in T-cell recognition and tumour clearance. Combining such approaches with PD-1/PD-L1 inhibitors produces synergistic effects that raise response rates by 20–40%. Furthermore, HLA class I status assessment can serve as an emerging possible biomarker for immunotherapy success. However, tumour heterogeneity and immunosuppressive microenvironments remain a challenge. Crucially, clinical studies to validate HLA class I restoration strategies and biomarker-driven patient stratification are underway to Investigate interactions between natural killer cell responses and HLA class I to help improve therapeutic approaches. Targeting therapies to reverse HLA class I defects through oncolytic viruses, along with integrating these with tailored immunotherapies are suggested future directions in immunotherapy.

  • Progress and Prospects in HIV Vaccine Development: A Comprehensive Review

    by Vivian Ukamaka Nwokedi, Comfort Ohunene Mathew, Enibokun Theresa Orobator, Ikechukwu Kanu, Olukunle O. Akanbi, Bankole Israel Adeyemi, Josephat Chisom Uzochukwu, Abdulmojeed Aishat O

    HIV/AIDS has been a disease condition affecting the entire world since its discovery in the 1980s, with over 38 million people in the globe living with the virus. Several attempts, research and funds have been channelled towards discovering a cure for HIV/AIDS yet no cure has been discovered. Considering the burden associated with the disease condition, having a vaccine to help control the spread will be a great approach in the course of achieving universal control coverage of the disease condition and an end to the disease over time. In this review we examined the progress, challenges, and future directions in HIV vaccine development and various types of vaccine candidates currently under investigation, highlighting key drug candidates that failed to provide protection against HIV such as PrEPVacc, HVTN 505, Uhambo (HVTN 702), Imbokodo (HVTN 705) and Mosaico (HVTN 706) as well as RV144 that provided 31.2% protection against HIV in a modified intent-to-treat analysis and those whose investigations are still in progress. The search for HIV Vaccine continues despite the modest success of some vaccines in clinical trials due to diversity in genetic nature of HIV, its ability to mutate rapidly, and the difficulty of eliciting a sustained immune response. Hence we also reviewed current approaches to improve on the success rate recorded by RV144.


  • Biomarkers for Tuberculosis Diagnosis and Monitoring: A Review of Translational Progress

    by Olabisi Promise Lawal, Olufemi Adesola Adedayo, Sokoya Itunuoluwa Dorcas, Olukunle O. Akanbi, Bostock Chinecherem Okafor, Ikechukwu Kanu, Precious Esong Sone, John Opeyemi Patrick, Taiwo Oluwole Fabiyi, Bankole Israel Adeyemi, et al.

    Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.